Corvus Pharmaceuticals

Price & Volume

Stats

52W Range	$1.30-$10
Market Cap	$575.1M
Shares Short	2M

Financials

Revenue (12 Mos)	$0
Revenue Growth (YoY)	0%
Gross Profit (12 Mos)	$0
Diluted EPS	-$0.99

News

Yahoo Finance • last year

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Yahoo Finance • last year

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Yahoo Finance • last year

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Yahoo Finance • last year

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

About

CEO	Dr. Richard A. Miller M.D.
Address	863 Mitten Road, Burlingame, CA, United States, 94010
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	28